Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer.
作者信息
Sadoff Jerald, Davis Kourtney, Douoguih Macaya
机构信息
Janssen Vaccines and Prevention, Leiden, the Netherlands
出版信息
N Engl J Med. 2021 May 20;384(20):1965-1966. doi: 10.1056/NEJMc2106075. Epub 2021 Apr 16.
Abstract
摘要
相似文献
1
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer.
N Engl J Med. 2021 May 20;384(20):1965-1966. doi: 10.1056/NEJMc2106075. Epub 2021 Apr 16.
2
Vaccine-induced immune thrombotic thrombocytopenia in a male after Ad26.COV2.S vaccination presenting as cerebral venous sinus thrombosis.
Platelets. 2022 Jul 4;33(5):797-800. doi: 10.1080/09537104.2022.2071854. Epub 2022 May 9.
3
Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies.
Am J Hematol. 2022 May;97(5):519-526. doi: 10.1002/ajh.26488. Epub 2022 Feb 21.
4
Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.
Infection. 2023 Dec;51(6):1657-1667. doi: 10.1007/s15010-023-02035-6. Epub 2023 Apr 17.
5
Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination.
Ann Emerg Med. 2021 Oct;78(4):511-514. doi: 10.1016/j.annemergmed.2021.04.035. Epub 2021 Jul 3.
6
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
JAMA. 2021 Jun 22;325(24):2448-2456. doi: 10.1001/jama.2021.7517.
7
Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.
Ann Intern Med. 2022 Apr;175(4):513-522. doi: 10.7326/M21-4502. Epub 2022 Jan 18.
8
Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S.
Vaccine. 2023 Aug 23;41(37):5351-5359. doi: 10.1016/j.vaccine.2023.07.013. Epub 2023 Jul 28.
9
Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies.
Futur J Pharm Sci. 2022;8(1):20. doi: 10.1186/s43094-022-00409-5. Epub 2022 Mar 26.
10
Vaccine-Induced Immune Thrombotic Thrombocytopenia with Concurrent Arterial and Venous Thrombi Following Ad26.COV2.S Vaccination.
J Stroke Cerebrovasc Dis. 2021 Dec;30(12):106113. doi: 10.1016/j.jstrokecerebrovasdis.2021.106113. Epub 2021 Sep 20.
引用本文的文献
1
The Application of mRNA Technology for Vaccine Production-Current State of Knowledge.
Vaccines (Basel). 2025 Apr 4;13(4):389. doi: 10.3390/vaccines13040389.
2
Unraveling Cardiovascular Risks and Benefits of COVID-19 Vaccines: A Systematic Review.
Cardiovasc Toxicol. 2025 Feb;25(2):306-323. doi: 10.1007/s12012-024-09954-2. Epub 2025 Jan 18.
3
The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia.
Vaccines (Basel). 2024 May 20;12(5):559. doi: 10.3390/vaccines12050559.
4
COVID-19 vaccine (Ad26.COV2.S), an unlikely culprit of portal vein thrombosis in a middle-aged man.
Thromb Update. 2022 Aug;8:100119. doi: 10.1016/j.tru.2022.100119. Epub 2022 Jul 31.
5
COVID-19 in City Council Civil Servants, 1 March 2020-31 January 2023: Risk of Infection, Reinfection, Vaccine Effectiveness and the Impact of Heterologous Triple Vaccination.
Vaccines (Basel). 2024 Feb 28;12(3):254. doi: 10.3390/vaccines12030254.
6
Epidemiology, pathogenesis, and management of Coronavirus disease 2019-associated stroke.
Front Med. 2023 Dec;17(6):1047-1067. doi: 10.1007/s11684-023-1041-7. Epub 2024 Jan 2.
7
Transient Autoreactive PF4 and Antiphospholipid Antibodies in COVID-19 Vaccine Recipients.
Vaccines (Basel). 2023 Dec 14;11(12):1851. doi: 10.3390/vaccines11121851.
8
Intravenous Administration of Ad26.COV2.S Does Not Induce Thrombocytopenia or Thrombotic Events or Affect SARS-CoV-2 Spike Protein Bioavailability in Blood Compared with Intramuscular Vaccination in Rabbits.
Vaccines (Basel). 2023 Nov 30;11(12):1792. doi: 10.3390/vaccines11121792.
9
FcRIIa - dependent platelet activation identified in COVID-19 vaccine-induced immune thrombotic thrombocytopenia-, heparin-induced thrombocytopenia, streptokinase- and anisoylated plasminogen-streptokinase activator complex-induced platelet activation.
Front Cardiovasc Med. 2023 Nov 15;10:1282637. doi: 10.3389/fcvm.2023.1282637. eCollection 2023.
10
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.
PLoS Pathog. 2023 Nov 1;19(11):e1011744. doi: 10.1371/journal.ppat.1011744. eCollection 2023 Nov.
本文引用的文献
1
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.
N Engl J Med. 2021 May 20;384(20):1964-1965. doi: 10.1056/NEJMc2105869. Epub 2021 Apr 14.
2
Cerebral venous sinus thrombosis.
J Thromb Haemost. 2018 Oct;16(10):1918-1931. doi: 10.1111/jth.14210. Epub 2018 Jul 11.
Zotero 插件